Search

Your search keyword '"Konstantinov DN"' showing total 2 results
Start Over Author "Konstantinov DN" Search Limiters Available in Library Collection
2 results on '"Konstantinov DN"'

1. Therapeutic results in three cases of ganglioneuroblastoma associated with opsoclonus myoclonus ataxia syndrome.

Author

Shtarbanov IA, Boronsuzov IK, Chakarov IR, and Konstantinov DN

Subjects
Combined Modality Therapy, Female, Ganglioneuroblastoma complications, Ganglioneuroblastoma pathology, Humans, Infant, Opsoclonus-Myoclonus Syndrome complications, Opsoclonus-Myoclonus Syndrome pathology, Paraneoplastic Syndromes, Nervous System complications, Paraneoplastic Syndromes, Nervous System pathology, Treatment Outcome, Ganglioneuroblastoma therapy, Opsoclonus-Myoclonus Syndrome therapy, Paraneoplastic Syndromes, Nervous System therapy
Abstract

Competing Interests: None

Published
2020
Full Text
View/download PDF

2. Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor.

Author

Avramova BE, Yordanova MN, Konstantinov DN, and Bobev DG

Subjects
Adolescent, Antigens, CD34 metabolism, Benzylamines, Blood Cell Count, Child, Cyclams, Hematopoietic Stem Cell Mobilization adverse effects, Hematopoietic Stem Cell Mobilization methods, Heterocyclic Compounds adverse effects, Humans, Leukapheresis methods, Male, Transplantation, Autologous, Treatment Outcome, Granulocyte Colony-Stimulating Factor administration & dosage, Heterocyclic Compounds administration & dosage, Neoplasms therapy, Peripheral Blood Stem Cell Transplantation methods
Abstract

This paper describes the successful mobilization of peripheral blood stem cells for autologous transplantation in three children with malignant diseases by using plerixafor (Mozobil; Genzyme Corporation, Cambridge, MA) and granulocyte-colony stimulating factor (G-CSF) after failed previous mobilizations. A median sixfold increase in the number of circulating CD34+ cells after plerixafor treatment as compared with the baseline level was observed. An optimal CD34+ cell count for transplantation with one or two leukapheresis sessions was achieved. Mobilization using plerixafor was found to be safe with no adverse events. Therefore, the combination of G-CSF and plerixafor in children results in effective increases in peripheral CD34+ cell counts and reduces the risk of mobilization failure.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results